ASX biotech sector’s best EOFY

  1. 522 Posts.
    lightbulb Created with Sketch. 119

    Bioxyne stars with a 720% gain in the 2024-25 yearParadigm shares soar 34% after $41 million convertible note dealBiotechs turn to debt funding

    The ASX biotech sector’s best EOFY performer has come from left field: the local and European focused medicinal cannabis supplier


    Bioxyne (ASX:BXN)
    .

    According to the Health Check Biotech Pulse – trademark pending – Bioxyne shares soared 720% in 2024-25, leaving its largely poorly performing pot peers in the dust.

    Bioxyne’s fortunes have been driven by its Breathe Life Sciences arm, which purveys cannabis products including not just flowers and oils but pastilles, vapes, pessaries and suppositories (we kid you not).

    The company recently upgraded full-year revenue guidance from $25 to $28 million and promised positive cash flow and – gasp! – profitability.

    reported by Stickhead today

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
5.3¢
Change
0.002(3.92%)
Mkt cap ! $114.7M
Open High Low Value Volume
5.1¢ 5.6¢ 5.1¢ $645.1K 12.17M

Buyers (Bids)

No. Vol. Price($)
3 369634 5.2¢
 

Sellers (Offers)

Price($) Vol. No.
5.3¢ 491581 2
View Market Depth
Last trade - 16.10pm 11/08/2025 (20 minute delay) ?
BXN (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.